Skip to main content
SpringerLink
Log in

Foreword

  • Foreword
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6):829–35.

    Article  PubMed  Google Scholar 

  2. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–7.

    Article  CAS  PubMed  Google Scholar 

  3. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31 e1–15.

  4. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. NEJM. 2003;349(21):2014–22.

    Article  CAS  PubMed  Google Scholar 

  5. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–32 (discussion 32).

    Article  CAS  PubMed  Google Scholar 

  6. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.

    Article  PubMed  Google Scholar 

  7. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55. doi:10.1136/annrheumdis-2013-203696.

  8. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthr Rheum. 2012;64(8):2504–17.

    Article  CAS  Google Scholar 

  9. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90.

    Article  CAS  PubMed  Google Scholar 

  10. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2005;52(10):3279–89.

    Article  CAS  Google Scholar 

  11. Kavanaugh A, Antoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Wu JJ. Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. JAMA. 2013;310(10):1075–6.

    Article  CAS  PubMed  Google Scholar 

  13. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum. 2007;56(9):2905–12.

    Article  CAS  Google Scholar 

  14. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82.

    Article  PubMed  Google Scholar 

  15. de Eusebio E, Armario-Hita JC, de Miquel DVA. Treatment of Psoriasis: focus on clinic-based management with Infliximab. Am J Clin Dermatol. 2014. doi:10.1007/s40257-013-0054-4.

  16. Campos Muñoz L, de Unamuno Bustos B, Herranz Pinto P, et al. Infliximab treatment of Psoriasis in supervised infusion centers: case management experience. Am J Clin Dermatol. 2014. doi:10.1007/s40257-013-0055-3.

Download references

Acknowledgments

This article was published in a supplement sponsored by the Inflammatory Autoimmunes Diseases Catedra of University of Alcalá, Madrid, Spain. The supplement was guest edited by Alice Bendix Gottlieb and Kristian Reich and peer reviewed by Enzo Berardesca and Howard Maibach, all of whom received honoraria to cover out of pocket expenses. A.B.G currently holds consulting or advisory board agreements with Amgen Inc., Astellas, Centocor (Janssen) Inc., Celgene Corp., Bristol Myers Squibb Co., Beiersdorf Inc., Abbot Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, and Glaxo Smith Kline. She has also received research and/or educational grants from Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene, Pfizer, Lilly, Coronado, and Levia. K.R. has received honoraria as a consultant and/or advisory board member and/or acted as a paid speaker and/or participated in clinical trials sponsored by AbbVie, Amgen, Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novarti, Ocean Pharma, Pfizer, Takeda, and Vertex. E.B. and H.M. have no conflicts of interest to declare.

Authors
  1. Alice Bendix Gottlieb
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gottlieb, A.B. Foreword. Am J Clin Dermatol 15 (Suppl 1), 3–4 (2014). https://doi.org/10.1007/s40257-013-0058-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-013-0058-0

Search

Navigation